Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked on a drug discovery partnership with Switzerland’s Haya Therapeutics, a move that underscores its commitment to advancing its anti-obesity portfolio. The collaboration will tap into Haya’s cutting-edge expertise in the dark genome, the largely non-protein-coding segment of DNA that has emerged as a crucial cell information processing unit.
Haya’s specialization in programmable therapeutics targeting regulatory RNAs from the dark genome, including the development of long non-coding RNAs (lncRNAs), positions the company at the forefront of genomic medicine. This science holds the potential to unlock new avenues for treating obesity and associated metabolic disorders.
Under the partnership, Haya will deploy its proprietary regulatory genome discovery platform to drive preclinical drug discovery, with a focus on obesity and metabolic conditions. The goal is to identify a suite of RNA-based drug targets derived from the regulatory genome to combat these medical challenges. Financially, Haya stands to gain upfront and milestone payments totaling up to USD 1 billion, complemented by royalties on future product sales. – Flcube.com
